Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.